Edgewise Therapeutics, Inc. (EWTX) Outlines Priorities For 2026

Shares closed 3% higher connected Tuesday, January 13, aft the institution provided a firm update and outlined its priorities for 2026. Major milestones for the existent twelvemonth see the anticipation of top-line findings for Sevasemten by the 4th quarter, which would beryllium the archetypal approved therapy for patients with Becker disease. On the different hand, Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is besides anticipating Phase 2 results for its selective cardiac sarcomere modulator, EDG-7500, during the archetypal fractional of the year, to dainty hypertrophic cardiomyopathy (HCM). The banal has a one-year mean stock terms people of $38.14, representing an upside imaginable of 58.06%, arsenic of January 12. Wall Street analysts stay bullish connected Edgewise with a statement Strong Buy rating. Recently, it has been connected the radar of respective probe firms. On December 24, Stifel Nicolaus maintained a Hold standing connected the banal with a $16 terms target. On the aforesaid day, JPMorgan expert Tessa Romero besides reiterated the firm’s Overweight standing connected the stock. Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is simply a biopharmaceutical institution processing therapeutics for muscular dystrophies and cardiac diseases. While we admit the imaginable of EWTX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock. READ NEXT: 14 Best S&P 500 Stocks to Buy Now and 11 Most Oversold S&P 500 Stocks Heading into 2026 Disclosure: None.